United Therapeutics Corporation $UTHR Stock Purchased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,014 shares of the biotechnology company’s stock after buying an additional 972 shares during the period. Illinois Municipal Retirement Fund owned 0.09% of United Therapeutics worth $21,683,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Toth Financial Advisory Corp boosted its holdings in United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 48 shares in the last quarter. Fiduciary Financial Advisors purchased a new position in shares of United Therapeutics in the 2nd quarter worth about $30,000. Gen Wealth Partners Inc purchased a new position in shares of United Therapeutics in the 3rd quarter worth about $34,000. Caitlin John LLC bought a new position in United Therapeutics in the 2nd quarter worth about $37,000. Finally, International Assets Investment Management LLC boosted its stake in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 1.1%

Shares of UTHR stock opened at $588.61 on Wednesday. The company has a 50 day moving average price of $536.90 and a 200-day moving average price of $534.57. United Therapeutics Corporation has a 52 week low of $449.58 and a 52 week high of $614.23. The firm has a market capitalization of $25.07 billion, a PE ratio of 22.21, a P/E/G ratio of 3.97 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. During the same period in the previous year, the firm earned $7.16 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. Analysts anticipate that United Therapeutics Corporation will post 24.47 earnings per share for the current year.

United Therapeutics declared that its Board of Directors has authorized a stock buyback program on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several analysts recently commented on UTHR shares. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. BTIG Research upped their target price on shares of United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. UBS Group set a $725.00 price target on shares of United Therapeutics in a report on Monday, October 19th. Jefferies Financial Group reissued a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a research report on Wednesday, October 14th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $368.00 price objective on shares of United Therapeutics in a report on Thursday, October 15th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $676.40.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, implying roughly 12% upside from the cited share price. HC Wainwright ratings
• Neutral Sentiment: The company announced participation in November investor conferences, giving investors an opportunity to hear updates but not signaling a specific business development. Investor conference announcement
• Neutral Sentiment: A report listed short interest at zero shares. That figure suggests no reported short position, but offers little clear directional signal for the stock.
• Negative Sentiment: CEO Martine Rothblatt sold shares in multiple transactions on November 6 and 9, while director Christopher Patusky also sold shares on November 9. Insider sales can raise concern about sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC filing

Insider Buying and Selling at United Therapeutics

In other news, Director Christopher Patusky sold 1,210 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $580.00, for a total transaction of $701,800.00. Following the transaction, the director directly owned 2,140 shares of the company’s stock, valued at $1,241,200. This represents a 36.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $598.67, for a total value of $4,968,961.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $27,043,121.24. The trade was a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 412,238 shares of company stock worth $220,071,746. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.